Concomitant CC and E2 Versus CC Alone in Ovulation Induction
Launched by MAHER ELESAWI KAMEL ELESAWI · Jul 8, 2014
Trial Information
Current as of August 27, 2025
Unknown status
Keywords
ClinConnect Summary
Women will be randomly divided into two groups; CC-E2 group and CC group. Women in the CC-E2 group will receive CC (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle). Women in the CC group will receive CC (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo mimic estradiol (for 5 consecutive days from day 2 of cycle). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 day...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Infertile women with eugonadotrophic anovulation/oligoovulation.
- • Unexplained infertility.
- Exclusion Criteria:
- • Age \< 20 or \> 35 years.
- • Body mass index (BMI) \< 18.5 kg/m2 or \> 25 kg/m2.
- • Presence of any infertility factor other than anovulation/oligoovulation.
- • Previous history of ovarian surgery or surgical removal of one ovary.
- • Previous exposure to cytotoxic drugs or pelvic irradiation.
- • Metabolic or hormonal abnormalities.
About Maher Elesawi Kamel Elesawi
Maher Elesawi Kamel Elesawi is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on rigorous scientific methodology and ethical standards, the organization collaborates with healthcare professionals and institutions to conduct comprehensive trials across various therapeutic areas. By leveraging cutting-edge technologies and fostering an environment of transparency and integrity, Elesawi aims to contribute significantly to the development of new treatments and enhance the understanding of complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mansoura, Dakahlia, Egypt
Mansoura, Dakahlia, Egypt
Mit Ghamr, Dakahlia, Egypt
Patients applied
Trial Officials
Ahmed M Badawy, Prof
Principal Investigator
Mansoura University
Maher E Kamel Elesawi, Dr
Study Director
Mansoura University
Mohamed S Abdelhafez, Dr
Study Director
Mansoura University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials